T1	Post-eligibility 0 58	Informed consent obtained prior to any screening procedure
T2	Person 60 69	Caucasian
T3	Person 70 74	male
T4	Person 78 84	female
*	OR T4 T3
T5	Value 94 111	At least 18 years
T6	Person 115 118	age
R1	Has_value Arg1:T6 Arg2:T5	
T7	Measurement 120 126	Weight
T8	Value 127 141	at least 45 kg
R2	Has_value Arg1:T7 Arg2:T8	
T9	Condition 175 200	chronic atopic dermatitis
T10	Qualifier 168 174	severe
T11	Qualifier 156 164	moderate
*	OR T10 T11
T12	Scope 156 174	moderate or severe
R3	Has_scope Arg1:T9 Arg2:T12	
T13	Condition 202 221	Good general health
T14	Observation 237 252	medical history
T15	Procedure 254 274	physical examination
T16	Procedure 279 304	laboratory determinations
T17	Negation 314 316	no
T18	Observation 317 357	signs of clinically significant findings
T19	Qualifier 326 348	clinically significant
R4	Has_qualifier Arg1:T18 Arg2:T19	
T20	Subjective_judgement 326 348	clinically significant
T21	Condition 366 391	chronic atopic dermatitis
T22	Negation 359 365	except
R5	Has_negation Arg1:T18 Arg2:T17	
R6	Has_negation Arg1:T21 Arg2:T22	
R7	AND Arg1:T17 Arg2:T21	
T23	Qualifier 222 304	ascertained by medical history, physical examination and laboratory determinations
R8	Has_qualifier Arg1:T13 Arg2:T23	
T24	Measurement 402 416	pregnancy test
T25	Value 393 401	Negative
R9	Has_value Arg1:T24 Arg2:T25	
T26	Condition 418 431	premenopausal
T27	Person 432 438	female
T28	Scope 418 438	premenopausal female
A1	Optional T28
R10	AND Arg1:T28 Arg2:T24	
T29	Post-eligibility 393 596	Negative pregnancy test (premenopausal female patient) at screening and use of adequate contraceptive measures (both male and female patients) throughout the study and 30 days after the last cis-UCA dose
